Solventum Corporation (NYSE: SOLV), a US-based company involved in advanced wound healing, announced on Monday that the US Food and Drug Administration (FDA) has granted 510(k) clearance for the combined use of Restrata Synthetic Electrospun Fiber Matrix and Solventum VAC Therapy.

Following Solventum's acquisition of Acera Surgical in December 2025, the company says that this regulatory milestone brings two advanced technologies together into one path to support active wound healing.

Restrata is a 100% synthetic, fully resorbable matrix engineered to support soft tissue healing. It supports tissue formation through structural cues rather than growth factors to create the foundation for soft tissue repair. Built to perform in challenging wound environments and resist enzymatic degradation, Restrata Matrix allows for cellular infiltration, neovascularisation and organised collagen deposition.

VAC Therapy delivers negative pressure wound therapy (NPWT) to create an environment that promotes wound healing. When used with dressings like Solventum VAC Peel and Place Dressing, VAC Therapy helps maintain close contact between the matrix and the wound bed. Macrostrain draws wound edges together, while microstrain stimulates cell proliferation, angiogenesis and granulation tissue formation. It promotes perfusion, reduces oedema and removes fluid and infectious material for up to seven days per application.

The company adds that, when applied together, Restrata Matrix provides structural support for soft tissue repair, while VAC Therapy helps create an optimised environment that supports tissue integration. Restrata Matrix's fully synthetic profile enables resistance to enzymatic degradation and aligns with VAC Peel and Place Dressing's wear time of up to seven days, whereas many collagen-based dressings degrade prematurely and therefore aren't optimal for concomitant use. Together, these therapies may allow for fewer dressing changes, less disruption to the healing environment and a more predictable workflow for care teams.